2-(2-甲氧基吡啶-4-基)乙酸 | 464152-38-3

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-(2-甲氧基吡啶-4-基)乙酸
• 英文名称: 2-(2-Methoxypyridin-4-yl)acetic acid
• CAS: 464152-38-3
• 化学式: C₈H₉NO₃
• mdl: MFCD10698166
• 分子量: 167.16
• InChiKey: TYKCMUMGTIJEMN-UHFFFAOYSA-N

物化性质

• 沸点：
  318.0±27.0 °C(Predicted)
• 密度：
  1.246±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

文献信息

• CDK2 INHIBITORS
  申请人：Pfizer Inc.

  公开号：US20200247784A1

  公开（公告）日：2020-08-06

  This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R 1 , R 2 and R 3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

  本发明涉及式(I)的化合物及其对映体，以及式(I)及其对映体的药用盐，其中R1、R2和R3如本文所定义。该发明还涉及包括这些化合物和盐的药物组合物，以及使用这些化合物、盐和组合物治疗需要的受试者中的异常细胞生长，包括癌症的方法和用途。
• CDK2 inhibitors
  申请人：Pfizer Inc.

  公开号：US11014911B2

  公开（公告）日：2021-05-25

  This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

  本发明涉及式（I）化合物 及其对映体，以及式（I）和所述对映体的药学上可接受的盐，其中 R1、R2 和 R3 如本文所定义。本发明进一步涉及包含此类化合物和盐的药物组合物，以及此类化合物、盐和组合物用于治疗需要者异常细胞生长（包括癌症）的方法和用途。
• 3-CARBONYLAMINO-5-CYCLOPENTYL-1H-PYRAZOLE COMPOUNDS HAVING INHIBITORY ACTIVITY ON CDK2
  申请人：Pfizer Inc.

  公开号：EP3917913A2

  公开（公告）日：2021-12-08
• [EN] CDK2 INHIBITORS<br/>[FR] INHIBITEURS DE CDK2
  申请人：PFIZER

  公开号：WO2020157652A2

  公开（公告）日：2020-08-06

  This invention relates to compounds of Formula (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.